Revenue Beat: Blue Jet Healthcare Limited Beat Analyst Estimates By 34%
A week ago, Blue Jet Healthcare Limited (NSE:BLUEJET) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. Statutory earnings performance was extremely strong, with revenue of ₹3.8b beating expectations by 34% and earnings per share (EPS) of ₹5.46, an impressive 24%ahead of expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
After the latest results, the five analysts covering Blue Jet Healthcare are now predicting revenues of ₹12.5b in 2027. If met, this would reflect a notable 13% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to climb 16% to ₹17.49. In the lead-up to this report, the analysts had been modelling revenues of ₹11.8b and earnings per share (EPS) of ₹16.91 in 2027. It looks like there's been a modest increase in sentiment following the latest results, withthe analysts becoming a bit more optimistic in their predictions for both revenues and earnings.
Check out our latest analysis for Blue Jet Healthcare
Althoughthe analysts have upgraded their earnings estimates, there was no change to the consensus price target of ₹565, suggesting that the forecast performance does not have a long term impact on the company's valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Blue Jet Healthcare at ₹720 per share, while the most bearish prices it at ₹370. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting Blue Jet Healthcare's growth to accelerate, with the forecast 29% annualised growth to the end of 2027 ranking favourably alongside historical growth of 15% per annum over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 12% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Blue Jet Healthcare is expected to grow much faster than its industry.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Blue Jet Healthcare following these results. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Blue Jet Healthcare going out to 2029, and you can see them free on our platform here..
You should always think about risks though. Case in point, we've spotted 1 warning sign for Blue Jet Healthcare you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.